ABEO
Abeona Therapeutics Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
6.10
▲ 0.14 (2.38%)
MARKET · —
Price
Open
6.15
Prev close
5.96
Day high
6.14
Day low
6.01
Volume
880.22K
Market cap
—
P/E (TTM)
—
52W range
4.00 – 7.65
Trailing performance
Returnvs SPY
1W
+1.67%
+3.0%
1M
-4.55%
-8.3%
3M
+10.33%
+7.2%
6M
+15.78%
+4.7%
YTD
+15.56%
+3.3%
1Y
-13.00%
-33.0%
3Y
+71.07%
-3.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
6.49
-6.02% from price
SMA 20
6.52
-6.56% from price
SMA 50
6.35
-4.15% from price
SMA 100
5.89
+3.65% from price
SMA 200
5.42
+12.44% from price
EMA 12
6.35
-3.98% from price
EMA 26
6.44
-5.28% from price
EMA 50
6.31
-3.36% from price
RSI (14)
43.2
Neutral
MACD (12,26,9)
-0.09
Hist -0.12
ATR (14)
0.40
6.53% of price
Realised vol 30D
67.3%
Annualised
Bollinger upper
7.55
20, 2σ
Bollinger lower
5.49
20, 2σ
50 / 200 cross
Golden
6.35 vs 5.42
Trend bias
Above 200
+12.44%
Risk profile
Beta vs SPY
1.43
More volatile than market
Correlation to SPY
0.34
Loosely linked
Realised vol 30D
67.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-42.3%
Peak to trough
Max drawdown 5Y
-93.3%
Peak to trough
ATR 14
0.40
6.53% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone
Insider Monkey · 1d ago
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ...
GuruFocus.com · 5d ago
ABEO: Zevaskyn® Launch Gains Momentum
Zacks Small Cap Research · 5d ago
Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating
MT Newswires · 8d ago
Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary
Moby · 9d ago
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires · 9d ago
Sector Update: Healthcare
MT Newswires · 9d ago
Abeona Therapeutics Shares Fall After Q2 Miss
MT Newswires · 9d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.